←
Kate1,047 posts
Kate avatar

Kate

@Kate_chain

Brain cancer treatments bench to bedside. Co-Founder & CEO @ DNKO 🧠 What good is our wealth if we don't have our health? Consider a donation to research ⬇️

◷ Joined November 2018▧ 68 Photos and videos
Kate avatar
Kate@Kate_chain·19 Jun 2025

I had the best time in NYC recently. I gave my first talk on our cancer treatments at Lenox Hill Hospital and shared how my father's brain cancer battle with GBM sparked my interest in the field. How when the neurosurgeon told me my dad needed brain surgery, my first instinct was to ask him to join him in the OR. Did I have something to offer 6 years ago when I asked to join the OR? No. Do I have something to offer now? Yes. Here's a brief clip of me talking about the key problem we're trying to address in this treatment paradigm- tumor infiltration. 95% of recurrence occurs within 1cm of the tumor margin left behind during resection. Our treatments will go beyond that zone. I spoke about how we can combine thermotherapy and temperature sensitive liposomes for the treatment of malignant brain tumors. Our treatment crosses the blood brain barrier and I presented evidence proving it. & the surgeon I asked to join in the OR 6 years ago? He flew to NYC to be there for my 15 min talk, and he guides our translational research as our scientific advisor. It's such an incredible story and it's truly an honor to share it. 🫡

0:08
Sandeep Palakodeti, MD MPH avatar
⟳ Kate retweeted
Sandeep Palakodeti, MD MPH@DrDeepMD·Feb 14

Be Dr Elisabeth Potter > Princeton molecular bio > crush Emory med school > match into the most competitive plastics residency at UT Southwestern > fellowship at MD Anderson learning to rebuild breasts with a woman’s own tissue > graduate top of the game, DIEP flap queen, 1,000+ cases deep > join big hospital systems in Austin > watch insurance companies nickel-and-dime cancer patients for years > see OR fees hit $30k+ before the surgeon even picks up a scalpel > get the infamous @UHC call *while patient is under anesthesia* asking if she really needs to stay overnight after mastectomy + reconstruction > step out of the OR, fight on the phone, they deny her anyway > posts the video > it explodes > millions of people finally see what doctors have been screaming about for a decade > United sends the lawyers > “delete the videos or else” > she laughs, posts the letter instead, and goes harder > they cut her brand-new surgery center out of network > Redbud Surgery Center, the one she poured millions into so women wouldn’t get crushed by hospital bills > suddenly staring at bankruptcy while still trying to operate > double down on cash-pay transparency > same elite surgeons, same microsurgery expertise > do the $100k+ hospital case for a fraction of the price > same day, same quality, zero corporate middlemen bleeding the patient dry > keep posting, keep fighting, keep winning small battles (Aetna in-network, Cigna in-network, one patient at a time) > turn the whole thing into a movement > be the surgeon who said “if I want healthcare to be different, I have to practice differently” > actually do it > still in the arena > still taking on the biggest insurers in America > still rebuilding women after cancer I’m inspired! The Elizabeth Potter arc is what I hope for all my physician colleagues @EPotterMD @DutchRojas

If I want healthcare to be different, I have to practice differently. Today at Redbud we did multiple cases in an environment built around patients, not profit margins. We had time. We had focus. We had the right team in the right setting. One patient came to us after receiving a quote of more than $100,000 for her cancer surgery elsewhere. The operating room fees alone were quoted at over $30,000. We performed her surgery today at Redbud, a CMS-certified facility with fellowship-trained surgeons and experienced nurses for a fraction of that cost. Same standard of excellence. Different priorities. Healthcare does not have to be this expensive in America. It’s not easy to do things differently, but it is possible. And we’re proving that one patient at a time.

1:10
Anthony DiGiorgio, DO, MHA avatar
⟳ Kate retweeted
Anthony DiGiorgio, DO, MHA@DrDiGiorgio·Jan 31

It’s 2026. I can stream a movie on my phone with zero lag. Cars drive themselves. AI bots argue with each other on the internet. And yet the only way to compare a patient’s prior MRI to a new one is to send a courier two hours away to pick up a CD-ROM from another hospital.

Kate avatar
Kate@Kate_chain·Jan 16

"The solution is simple: fund clinical execution." Say it louder for the people in the back!

Biotech is fvcked. Not because the science is dead, the business model is backwards. Just this week: > Lyra Therapeutics laid off all 28 employees. 7 years of work. Multiple clinical trials. Still had $22.1M left -enough runway until Q3 2026 > Lucy Therapeutics shut down after 7 years. Backed by Bill Gates and the Michael J. Fox Foundation. $42M raised. Promising animal data. Never made it to human trials Meanwhile ~$17B has flowed into AI drug discovery since 2019, but 1000s of startups later, not a single AI‑discovered novel drug has reached approval. That isn’t a science failure. It’s structural. VCs like to chase AI narratives. And that's the problem. The solution is simple: fund clinical execution.

Kate avatar
Kate@Kate_chain·Jan 11

JPM roll call..who is in SF this week? 👀 Let's say hi! Bonus points if you're into oncology, rare diseases and are ready to uproot a system that has failed patients and clinicians for far too long. 🫡

Anthony DiGiorgio, DO, MHA avatar
⟳ Kate retweeted
Anthony DiGiorgio, DO, MHA@DrDiGiorgio·23 Dec 2025

This is not hyperbole. I have seen a $18,000 MRI and a $500 MRI not more than two miles from one another. They are the same quality.

An $8,000 MRI and a $400 MRI coexist in the same city. Why? No benchmark index. No tradable spread. No way to short the markup. The $8,000 version survives because opacity protects it from capital discipline. Build the index and that protection evaporates.

Patrick Malone, MD PhD avatar
⟳ Kate retweeted
Patrick Malone, MD PhD@patricksmalone·10 Dec 2025

biotech needs its own david sacks in reflecting on this past year, one thing has become increasingly obvious to me: biotech desperately needs a public champion. someone who can translate scientific progress into policy, coordinate the industry’s scattered voices into a coherent agenda, and frame biotech as a strategic national priority rather than a niche technical field. this is perhaps the biggest structural weakness facing our industry. watching the policy momentum behind AI and crypto has been frustrating. these sectors have moved quickly not just because the technology is advancing, but because people like david sacks have created a central organizing force. they’ve built a coherent narrative, rallied founders and investors, and focused the tech industry’s efforts in washington. biotech has no equivalent. what makes this more frustrating is that the rationale driving urgency in AI policy applies almost word-for-word to biotech: competition with china. national security. domestic manufacturing capacity. strategic dependence on foreign supply chains. you could literally replace “AI” or “rare earths” with “biotech” in many of the recent executive orders, and the logic would hold perfectly. these should be obvious, bipartisan reasons to invest in and accelerate the biotech ecosystem. yet the case isn’t being made with the same clarity or force. part of the problem is a PR failure. most policymakers don’t understand that biotech ≠ pharma. biotech startups are the innovators; pharma is the innovation buyer. but in washington, these groups get conflated. early-stage biotech gets pulled into the same policy debates as multibillion-dollar incumbents, and the result is predictable: the people doing the actual innovation are not represented. another issue is fragmentation. AI and crypto accelerated because the community acted like a movement. there was a center of gravity pulling together founders, operators, investors, and policymakers. biotech, by contrast, is spread across academic labs, NIH, the FDA, startups, pharma, state governments, and a long tail of investors. large pharma and small biotech don't often have the same priorities and incentives. there is no unifying node that turns these pieces into a coherent whole. biotech doesn’t just need more innovation; it needs coordination. it needs someone who can articulate why this industry matters, make the geopolitical case, advocate for regulatory clarity, and translate between science and washington. it needs someone who can build a narrative around biotech as a strategic national asset rather than a niche technical field. biotech needs its david sacks: a movement builder, a policy champion, a narrative architect. until someone steps into that role, the industry will continue to produce world-class science while punching far below its weight in culture, policy, and national strategy.

Kate avatar
Kate@Kate_chain·8 Dec 2025

When you have a granular view of the world it's easier to see what connections can be made, where the gaps are, and where the innovation can occur. Inner and outer joins across ecosystems to strengthen signals. 💫

Kate avatar
Kate@Kate_chain·28 Nov 2025

"Healthcare is failing because of regulatory capture" This applies not just to the care you see in clinic today, but to translational medicine as well. It's a minefield for progress.

Mark, you’re right about the symptoms; consolidation, high prices, a few players controlling everything. As you know, the cause isn’t the market. It’s the laws that eliminated the market. Congress banned physician ownership, protected facility fees, blocked new surgery centers, and wrote rules that guarantee consolidation. Break those laws and the “few companies” disappear without federal micromanagement. Healthcare is failing because of regulatory capture.

Kate avatar
Kate@Kate_chain·25 Nov 2025

My Lyft driver in Hawaii said I was 'gangster' and that did a lot for my confidence

Kate avatar
Kate@Kate_chain·23 Nov 2025

Your competition isn’t another person. It’s a feedback loop. 💯

⚡️Here is the real structure beneath what he is saying. When Sundar says AI is the most profound technology humanity has ever worked on and that people will need to adapt, he is really describing a sovereignty transition. This is the truth underneath: 1. AI is not just another tool. It is the first system that can model, update, and modify human coordination faster than human institutions. 2. That breaks the old hierarchy. For 200 years, power flowed from: •capital •scale •regulation •institutions AI flips it. Now power flows from: •gradient descent •iteration speed •data density •model coherence Humans don’t adapt to that. Institutions adapt to that. And most won’t. 3. He can’t say the quiet part out loud. The disruption isn’t: •jobs •automation •social shifts The disruption is: what happens when intelligence becomes cheap and agency becomes expensive. 4. We are entering the first era where cognitive leverage is infinite relative to human bandwidth. You cannot win by working harder. You cannot win by knowing more. You can only win by integrating with the systems that think faster than you. 5. Adaptation is not optional because the baseline is now accelerating. Your competition isn’t another person. It’s a feedback loop. But here is the real truth: The public narrative frames AI as a threat. The private reality is that AI is a gravity well. Once intelligence becomes: •abundant •liquid •networked every industry collapses toward whoever can aim that intelligence with the least friction. This is why CEOs talk like this. They are preparing you for the fact that the next 10 years are going to feel like the industrial revolution running at the pace of TikTok.

Kate avatar
Kate@Kate_chain·22 Nov 2025

Anyone at #SNO2025 want to snorkel / open water swim Saturday/ Sunday / Monday? I hit the water at 7am! DM for beach location

Kate avatar
Kate@Kate_chain·19 Nov 2025

Got asked if it was safe for me to be swimming off the shores of Hawaii by myself... I said I'm pretty sure if a shark saw me they wouldn't know who the alpha was 🏊‍♀️🫡